AbbVie Inc. (FRA:4AB)
Germany
· Delayed Price · Currency is EUR 155.80
+1.00 (0.65%)
At close: Apr 24, 2025, 10:00 PM CET
AbbVie Revenue
AbbVie had revenue of $13.34B USD in the quarter ending March 31, 2025, with 8.39% growth. This brings the company's revenue in the last twelve months to $57.37B, up 5.45% year-over-year. In the year 2024, AbbVie had annual revenue of $56.33B with 3.71% growth.
Revenue (ttm)
$57.37B
Revenue Growth
+5.45%
P/S Ratio
5.46
Revenue / Employee
$1.04M
Employees
55,000
Market Cap
289.64B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
| Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
| Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
| Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
| Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 35.15B |
| Siemens Aktiengesellschaft | 76.54B |
| Deutsche Telekom AG | 118.43B |
| Allianz SE | 107.35B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.15B |
| Rheinmetall AG | 9.75B |
| Siemens Energy AG | 35.76B |
| Merck KGaA | 21.16B |
AbbVie News
- 3 days ago - Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV - Accesswire
- 3 days ago - AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines - PRNewsWire
- 3 days ago - The Gross Law Firm Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - ABBV - PRNewsWire
- 4 days ago - Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights – ABBV - GlobeNewsWire
- 4 days ago - Shareholders that lost money on Cerevel Therapeutics Holdings, Inc. (ABBV) should contact Levi & Korsinsky about pending Class Action - ABBV - Accesswire
- 5 days ago - Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom - Barrons
- 5 days ago - Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders - PRNewsWire
- 6 days ago - Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewsWire